Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experimental cancer therapy INBRX-106, which could be valued at over $8 billion. • Inhibrx Biosciences stock is challenging resistance. Why did INBX hit a new high? The cancer-focused biotech is evaluating a potential joint spin-off of INBRX-106 alongside another early-stage oncology asset. Reuters on […]

Sportradar Group AG Shares Plummet 24%; $SRAD Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation

Business Men Break Sit Read Newspaper

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) — Block & Leviton is investigating Sportradar Group AG (NASDAQ:SRAD) for potential securities law violations. Investors who have lost money in their Sportradar Group AG investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/srad. What is this all about? […]